Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GPR3 | P46089 | 2/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28220033 | 0.78 | MAOA (0.54) | MAOAMAOBKDM4EGPR3PDE4A | |
| SCHEMBL30583086 | 0.78 | MAOA (0.54) | MAOAMAOBKDM4EGPR3PDE4A | |
| SCHEMBL18848440 | 0.78 | KDM4E (0.50) | KDM4EGPR3PDE4APDE4BPDE4C | |
| SCHEMBL15111074 | 0.76 | NR4A2 (0.46) | ALDH1A1CYP1A2ALOX15HSD17B10MEN1 | |
| SCHEMBL31384389 | 0.75 | MAOA (0.50) | MAOAMAOBKDM4EGPR3PDE4A | |
| SCHEMBL2125593 | 0.75 | MAOA (0.50) | MAOAMAOBKDM4EGPR3PDE4A | |
| SCHEMBL30409628 | 0.75 | MAOA (0.50) | MAOAMAOBKDM4EGPR3PDE4A | |
| SCHEMBL11295043 | 0.75 | ERN1 (0.55) | MAOAMAOBKDM4EGPR3PDE4A | |
| SCHEMBL201997 | 0.75 | MAOA (0.50) | MAOAMAOBKDM4EGPR3PDE4A | |
| SCHEMBL6822558 | 0.75 | MAOA (0.50) | MAOAMAOBKDM4EGPR3PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2024-02-22 | — | — | US | disclosed |
| EP-4232444-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022083569-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022083569-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-10654807-B2 | Toll-like receptor 8 agonists | THE UNIVERSITY OF KANSAS (US) | 2020-05-19 | — | — | US | disclosed |
| US-10654807-B2 | Toll-like receptor 8 agonists | THE UNIVERSITY OF KANSAS (US) | 2020-05-19 | — | — | US | disclosed |
| US-10023538-B2 | Compounds, compositions and associated methods comprising 3-aryl quinolines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180009760-A1 | COMPOUNDS, COMPOSITIONS AND ASSOCIATED METHODS COMPRISING 3-ARYL QUINOLINES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2018-01-11 | — | — | US | disclosed |
| US-9707239-B2 | Compounds that modulate oxidative stress | VTV THERAPEUTICS LLC (US) | 2017-07-18 | — | — | US | disclosed |
| EP-2802565-A1 | COMPOUNDS, COMPOSITIONS AND ASSOCIATED METHODS COMPRISING 3-ARYL QUINOLINES | Oregon Health & Science University (US) | 2014-11-19 | — | — | EP | disclosed |
| US-20140256949-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
| US-20130253007-A1 | Compounds That Modulate Oxidative Stress | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2013106847-A1 | COMPOUNDS, COMPOSITIONS AND ASSOCIATED METHODS COMPRISING 3-ARYL QUINOLINES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2013-07-18 | — | — | WO | disclosed |
| EP-2603218-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012094580-A2 | COMPOUNDS THAT MODULATE OXIDATIVE STRESS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-07-12 | — | — | WO | disclosed |
| US-20120071505-A1 | SUBSTITUTED PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE TO TREAT OXIDATIVE STRESS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2012021580-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | WO | disclosed |
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| WO-2011022216-A1 | SUBSTITUTED PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE TO TREAT OXIDATIVE STRESS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | MAOA 665/4885MAOB 555/4885KDM4E 542/4885 |
| US-10654807-B2 | Toll-like receptor 8 agonists | TLR8, TLR7, TLR1 | MAOA 1501/4885MAOB 2191/4885KDM4E 3567/4885 |
| US-10023538-B2 | Compounds, compositions and associated methods comprising 3-aryl quinolines | CYP3A43, ABL1, CYP3A7 | MAOA 310/4885MAOB 255/4885KDM4E 2481/4885 |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, HRAS, APC | MAOA 4814/4885MAOB 4672/4885KDM4E 4694/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | MAOA 4774/4885MAOB 4435/4885KDM4E 444/4885 |
| US-20120071505-A1 | SUBSTITUTED PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE TO TREAT OXIDATIVE STRESS | HMOX2, HMOX1, MPO | MAOA 234/4885MAOB 201/4885KDM4E 1780/4885 |
| US-20180009760-A1 | COMPOUNDS, COMPOSITIONS AND ASSOCIATED METHODS COMPRISING 3-ARYL QUINOLINES | CYP3A43, ABL1, CYP3A7 | MAOA 310/4885MAOB 255/4885KDM4E 2481/4885 |
| US-20140256949-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | MAOA 665/4885MAOB 555/4885KDM4E 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.